SARS Vaccine Development by Jiang, Shibo et al.
Developing effective and safe vaccines is urgently
needed to prevent infection by severe acute respiratory
syndrome (SARS)–associated coronavirus (SARS-CoV).
The inactivated SARS-CoV vaccine may be the first one
available for clinical use because it is easy to generate;
however, safety is the main concern. The spike (S) protein
of SARS-CoV is the major inducer of neutralizing antibod-
ies, and the receptor-binding domain (RBD) in the S1 sub-
unit of S protein contains multiple conformational
neutralizing epitopes. This suggests that recombinant pro-
teins containing RBD and vectors encoding the RBD
sequence can be used to develop safe and effective SARS
vaccines.
S
evere acute respiratory syndrome (SARS) is a newly
emerged infectious disease caused by SARS-associat-
ed coronavirus (SARS-CoV) (1). It originated in the
Guangdong province of China in late 2002, spread rapidly
around the world along international air-travel routes, and
resulted in 8,450 cases and 810 deaths in 33 countries and
areas on 5 continents (www.cdc.gov/mmwr/mguide_
sars.html). The global outbreak of SARS seriously threat-
ened public health and socioeconomic stability worldwide.
Although this outbreak was eventually brought under con-
trol in 2003, several isolated outbreaks of SARS subse-
quently occurred because of accidental releases of the
SARS-CoV isolates from laboratories in Taiwan,
Singapore, and mainland China (http://www.who.int/
csr/sars/en). In late 2003 and early 2004, new infections in
persons who had contact with animals infected with
SARS-CoV strains significantly different from those pre-
dominating in the 2002–2003 outbreak were reported in
Guangdong, China (1). These events indicate that a SARS
epidemic may recur at any time in the future, either by the
virus escaping from laboratory samples or by SARS-CoV
isolates evolving from SARS-CoV–like virus in animal
hosts.
Origin and Evolution of SARS-CoV 
Coronaviruses of the genus Coronavirus can be divided
into 3 antigenic groups. Group 1 consists of human coron-
avirus 229E (HCoV-229E), porcine epidemic diarrhea
virus, and feline infectious peritonitis virus (FIPV). Group
2 includes bovine coronavirus, murine hepatitis virus, and
human coronavirus OC34 (HCoV-OC43). Group 3 con-
tains avian infectious bronchitis virus. SARS-CoV is a
new member of the genus Coronavirus, but it does not
belong to any of the 3 antigenic groups, although some
reports suggest that it most resembles the group 2 coron-
avirus (2). SARS-CoV may have originated in animals.
SARS-CoV–like virus with >99% nucleotide homology
with human SARS-CoV was identified in palm civets and
other animals found in live animal markets in Guangdong,
China (3). The SARS-CoV–like virus that exists in ani-
mals does not cause typical SARS-like disease in the nat-
ural hosts and is not transmitted from animals to humans.
Under certain conditions, the virus may have evolved into
the early human SARS-CoV, with the ability to be trans-
mitted from animals to humans or even from humans to
humans, resulting in localized outbreaks and mild human
disease. Under selective pressure in humans, the early
human SARS-CoV may further evolve into the late human
SARS-CoV, which can cause local or even global out-
breaks and typical SARS in humans with high death rates.
Early human SARS-CoV is closer genetically to animal
SARS-CoV–like virus than to late human SARS-CoV,
which has a 29-nucleotide (in some isolates a 415-
nucleotide) deletion in open reading frame 8 (3,4). The
characteristics of these viruses are summarized in the
Table (4–6). 
SARS-CoV can be efficiently grown in cell culture (1)
and rapidly spread from person to person (7). It can sur-
vive in feces and urine at room temperature for >2 days
(http://www.who.int/csr/sars/en) and may cause serious,
even fatal, disease. SARS-CoV, a National Institute of
Allergy and Infectious Diseases Biodefense Category C
priority pathogen (http://www2.niaid.nih.gov/Biodefense/
bandc_priority.htm) could be used by bioterrorists as a bio-
logical weapon. Therefore, development of effective and
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epidemic and for biodefense preparedness. Currently, 3
major classes of SARS vaccines are under development: 1)
inactivated SARS-CoV (Figure 1), 2) full-length S protein
(Figure 2A), and 3) those based on fragments containing
neutralizing epitopes (Figure 2B).
Inactivated SARS-CoV–based Vaccines
SARS-CoV expresses several structural proteins,
including nucleocapsid, membrane, envelope, and spike
(S) proteins (1). All may serve as antigens to induce neu-
tralizing antibodies and protective responses. In general,
prior to identification of the protein that contains the major
neutralizing epitopes, the inactivated virus may be used as
the first-generation vaccine because it is easy to generate
whole killed virus particles. However, once the neutraliz-
ing epitopes are identified, the inactivated virus vaccine
should be replaced by vaccines based on fragments con-
taining neutralizing epitopes since they are safer and more
effective. Several reports have showed that SARS-CoV
inactivated with formaldehyde, UV light, and β-propiolac-
tone can induce virus-neutralizing antibodies in immu-
nized animals (8–11), and the first inactivated SARS-CoV
vaccine is being tested in the clinical trials in China.
However, safety of the inactivated vaccine is a serious con-
cern; production workers are at risk for infection during
handling of concentrated live SARS-CoV, incomplete
virus inactivation may cause SARS outbreaks among the
vaccinated populations, and some viral proteins may
induce harmful immune or inflammatory responses, even
causing SARS-like diseases (12,13). 
S Protein–based Vaccines
The S protein of SARS-CoV, a type I transmembrane
glycoprotein, is responsible for virus binding, fusion, and
entry and is a major inducer of neutralizing antibodies
(1,14). S protein consists of a signal peptide (SP: amino
acids [aa] 1–12) and 3 domains: an extracellular domain
(aa 13–1193), a transmembrane domain (aa 11194–1215),
and an intracellular domain (aa 1216–1255). Its extracellu-
lar domain consists of 2 subunits, S1 and S2 (14), although
the cleavage site between these subunits has not been
clearly defined. The S1 subunit is responsible for virus
binding to the receptor, angiotensin-converting enzyme 2
(ACE2) (15,16). A fragment located in the middle region
of the S1 subunit (aa 318–510) is the receptor-binding
domain (RBD) for ACE2 (17–19). SARS-CoV may also
bind to cells through the alternative receptors DC-SIGN or
L-SIGN (20,21), but the binding sites for these alternative
receptors have not been defined. The S2 subunit, which
contains a putative fusion peptide and 2 heptad repeats
(HR1 and HR2), is responsible for fusion between the viral
and target cell membranes. Infection by SARS-CoV is ini-
tiated by binding of RBD in the viral S protein S1 subunit
to ACE2 on target cells. This forms a fusogenic core
between the HR1 and HR2 regions in the S2 domain that
brings the viral and target cell membranes into close prox-
imity, which results in virus fusion and entry (22–24). This
scenario indicates that the S protein may be used as a vac-
cine to induce antibodies for blocking virus binding and
fusion. 
Several recombinant vector-based vaccines expressing
SARS-CoV S protein have been assessed in preclinical
studies. Yang et al. (25) reported that a candidate DNA
vaccine encoding the full-length S protein induced neutral-
izing antibodies (neutralizing titers ranging from 1:50 to
1:150) and protected mice from SARS-CoV challenge.
Using DNA vaccines encoding the full-length and seg-
ments of S protein to immunize rabbits, Wang et al. have
produced higher titers of neutralizing antibodies and
demonstrated that major and minor neutralizing epitopes
are located in the S1 and S2 subunits, respectively (26).
Other groups also found neutralizing epitopes in the S2
subunit (27,28). Bisht et al. (29) have shown that intranasal
or intramuscular inoculations of mice with highly attenuat-
ed modified vaccinia virus Ankara (MVA) vaccines encod-
ing full-length SARS-CoV S protein also produce
neutralizing antibodies with mean neutralizing titers of
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nization of African green monkeys with an attenuated
parainfluenza virus expressing S protein resulted in pro-
duction of neutralizing antibodies and protected animals
from infection by challenge with SARS-CoV. These data
suggest that the S protein can induce neutralizing antibod-
ies and protective responses in immunized animals. 
Using convalescent-phase sera from SARS patients and
a set of peptides spanning the entire sequence of the
SARS-CoV S protein, we have identified 5 linear immun-
odominant sites (IDS) in the S protein (Figure 2A). IDS I,
II, III, and V reacted with >50% of the convalescent-phase
sera from SARS patients, while IDS IV was reactive with
>80% of SARS sera, suggesting that IDS IV is the major
immunodominant epitope on the S protein (31). Synthetic
peptides corresponding to IDS could induce high titers of
S protein–specific antibodies, but none of these antibodies
possesses neutralizing activity. These findings suggest that
the IDS in S protein may not induce neutralizing antibod-
ies. Whether these antibodies enhance infection by heterol-
ogous SARS-CoV strains or mediate harmful immune
responses is unclear. The S protein of FIPV expressed by
recombinant vaccinia can cause antibody-dependent
enhancement of disease if vaccinated animals are subse-
quently infected with wild-type virus (32). Our previous
studies on HIV-1 showed that antibodies against some
immunodominant epitopes in the HIV-1 envelope glyco-
protein could enhance infection by heterologous HIV-1
strains (33). Most recently, Yang et al. (6) demonstrated
that the polyclonal and monoclonal antibodies against S
protein of the late SARS-CoV (Urbani strain) could neu-
tralize infection by the relevant late SARS-CoV strains.
However, these antibodies enhanced infection by an early
human SARS-CoV isolate (GD03T0013) and the civet
SARS-CoV–like viruses. These investigators have shown
that the ACE2-binding domain mediates the antibody-
dependent enhancement of civet SARS-CoV–like virus
entry (6). Theoretically, some antibodies to the ACE2-
binding domain may enhance infection if these antibodies
closely mimic the receptor ACE2 and induce similar con-
formational changes, as the receptor likely does. The S
protein with truncation at aa 1153 failed to cause antibody-
dependent enhancement of infection, although it still
induced neutralizing antibodies. This finding suggests that
removal of the aa 1153–1194 region may abrogate induc-
tion of virus infection–enhancing antibodies (6).
Vaccination of ferrets with MVA-based SARS vaccine
expressing full-length S protein caused liver damage after
animals were challenged with SARS-CoV (34). These
findings raised concerns about the efficacy and safety of
the vaccines containing or expressing full-length S protein. 
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Figure 1. Strategy for designing vaccines for severe acute respira-
tory syndrome (SARS) using inactivated SARS-associated coron-
avirus. This virus expresses several structural proteins, including
nucleocapsid (N), membrane (M), envelope (E), and spike (S). 
Figure 2. Strategies for designing vaccines for severe acute respiratory syndrome (SARS) using A) spike (S) protein and B) fragments
containing neutralizing epitopes. SP, signal peptide; RBD, receptor binding domain; FP, fusion peptide; HR, heptad repeat; TM, trans-
membrane domain; CP, cytoplasm domain. IDS, immunodominant sites I to V corresponding to the sequences of amino acid residues 9-
71, 171–224, 271–318, 528–635, and 842–913, respectively. The residue numbers of each region correspond to their positions in the S
protein of SARS-associated coronavirus (SARS-CoV) strain Tor2. RBD contains the major neutralizing epitopes in the S protein. The
recombinant RBD may be used as an efficacious and safe vaccine for preventing infection by SARS-CoV strains with distinct genotypes.Vaccines Based on Fragments 
Containing Neutralizing Epitopes
RBD, a fragment (≈193 aa residues) in the middle of S1
subunit of S protein (Figure 2B), is responsible for virus
binding to the receptor on target cells. We have demonstrat-
ed that the antisera from SARS patients and from animals
immunized with inactivated SARS-CoV reacted strongly
with RBD (9,35). Absorption of antibodies by RBD from
these antisera results in the removal of most of the neutral-
izing antibodies, and RBD-specific antibodies isolated from
these antisera have potent neutralizing activity (35,36). We
have also shown that rabbits and mice immunized with
RBD produced high titers of neutralizing antibodies against
SARS-CoV with 50% neutralizing titers at a >1:10,000
serum dilution (37). The immunized mice were protected
from SARS-CoV challenge (unpub. data). The antibodies
purified from the antisera against SARS-CoV significantly
inhibited RBD binding to ACE2 (9,36–38). Using spleen
cells from mice immunized with RBD, we have generated
a panel of 25 monoclonal antibodies (MAbs) that recognize
different conformational epitopes on RBD and possess
potent neutralizing activity (38). Our result is in agreement
with the report by van den Brink et al. (39), who identified
3 human neutralizing anti-S MAbs from antibody phage
display libraries by using inactivated SARS-CoV as the tar-
get. These researchers also found that all of these MAbs
specifically bound to RBD and blocked interaction between
RBD and ACE2. These findings suggest that RBD contains
the major neutralizing epitopes in the S protein and is an
ideal SARS vaccine candidate because RBD contains the
receptor-binding site, which is critical for virus attachment
to the target cell for infection (15,17–19). Antibodies spe-
cific for RBD are expected to block binding of virus to the
target cell. RBD induces higher titers of neutralizing anti-
bodies than those vaccines expressing the full-length S pro-
tein (25,26,29,30,37,38). RBD sequences among the late
SARS-CoV strains are highly conserved. When the early
and late SARS-CoV strains are compared, only 3 to 5 aa
residues are variable among the 193 residues in RBD and
most of the isolates vary by only 1 residue (4). van den
Brink et al. (39) showed that 1 human MAb (CR3014) spe-
cific for RBD of SARS-CoV strain FM1 can effectively
bind to most RBDs of the early and late SARS-CoV strains.
These data suggest that antibodies directed against RBD of
a SARS-CoV isolate may neutralize infection by a broad
spectrum of SARS-CoV strains. Therefore, recombinant
proteins containing RBD or vectors encoding RBD may be
used as vaccines for preventing infection by SARS-CoV
with distinct genotypes.
Conclusions
An ideal SARS vaccine should 1) elicit highly potent
neutralizing antibody responses against a broad spectrum
of viral strains; 2) induce protection against infection and
transmission; and 3) be safe by not inducing any infection-
enhancing antibodies or harmful immune or inflammatory
responses. Currently, an inactivated SARS-CoV vaccine is
in clinical trials in China. Safety is the major concern for
this type of vaccine (12). The S protein is the major induc-
er of neutralizing antibodies. Recombinant vector-based
vaccines expressing full-length S protein of the late SARS-
CoV are under development. These vaccines can induce
potent neutralizing and protective responses in immunized
animals but may induce antibodies that enhance infection
by early human SARS-CoV and animal SARS-CoV–like
viruses (6). Recent studies have demonstrated that recom-
binant RBD consists of multiple conformational neutraliz-
ing epitopes that induce highly potent neutralizing
antibodies against SARS-CoV (9,26,35–38). Unlike full-
length S protein, RBD does not contain immunodominant
sites that induce nonneutralizing antibodies. RBD
sequences are relatively conserved. Thus, recombinant
RBD or vectors encoding RBD may be used as safe and
efficacious vaccines for preventing infection by SARS-
CoV with distinct genotypes.
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